| Literature DB >> 27329501 |
Nguyen Thi Khanh Nhu1,2, David W Riordan3, Tran Do Hoang Nhu1, Duy Pham Thanh1, Guy Thwaites1,4, Nguyen Phu Huong Lan5, Brendan W Wren3, Stephen Baker1,3,4, Richard A Stabler3.
Abstract
Acinetobacter baumannii is a significant cause of opportunistic hospital acquired infection and has been identified as an important emerging infection due to its high levels of antimicrobial resistance. Multidrug resistant A. baumannii has risen rapidly in Vietnam, where colistin is becoming the drug of last resort for many infections. In this study we generated spontaneous colistin resistant progeny (up to >256 μg/μl) from four colistin susceptible Vietnamese isolates and one susceptible reference strain (MIC <1.5 μg/μl). Whole genome sequencing was used to identify single nucleotide mutations that could be attributed to the reduced colistin susceptibility. We identified six lpxACD and three pmrB mutations, the majority of which were novel. In addition, we identified further mutations in six A. baumannii genes (vacJ, pldA, ttg2C, pheS and conserved hypothetical protein) that we hypothesise have a role in reduced colistin susceptibility. This study has identified additional mutations that may be associated with colistin resistance through novel resistance mechanisms. Our work further demonstrates how rapidly A. baumannii can generate resistance to a last resort antimicrobial and highlights the need for improved surveillance to identified A. baumannii with an extensive drug resistance profile.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27329501 PMCID: PMC4916428 DOI: 10.1038/srep28291
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Antimicrobial susceptibility profiles of the parent A. baumannii strains used in this study.
| Isolate | Date | AMP | TZP | IMP | AMK | OFX | CAZ | CRO | SXT | FEP | GEN | CST | NDM -1 | OXA -51 | OXA -23 | OXA -24 | OXA -58 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BAL 062 | Apr-09 | R | R | R | R | R | R | R | R | R | R | S | – | + | + | – | – |
| BAL 242 | Jan-11 | R | R | R | R | R | R | R | R | R | R | S | – | + | + | – | – |
| BAL 255 | Feb-11 | R | S | R | R | R | R | R | R | R | R | S | + | + | – | – | + |
| BAL 266 | Feb-11 | R | S | S | S | S | S | S | S | S | S | S | – | + | – | – | – |
AMP; ampicillin, TZP; piperacillin/tazobactam, IMP; imipenem, AMK; amikacin, OFX; Ofloxacin, CAZ; ceftazidime, CRO; ceftriaxone, SXT; co-trimoxazole, FEP; cefepime, GEN; gentamycin, CST; colistin.
Genome characteristics of the sequenced A. baumannii isolates in this study.
| Isolate | Bp (GC%) | Coverage | CDSs | ST | Origin | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BAL 062 | 4,028,838 (38.99) | 41.2x | 3,960 | 1 | 3 | 3 | 2 | 2 | 16 | 3 | ST136 | This study |
| BAL 242 | 3,912,277 (38.91) | 33.6x | 3,786 | 1 | 15 | 3 | 2 | 2 | 106 | 3 | ST493 | This study |
| BAL 255 | 3,953,867 (39.02) | 64.5x | 3,752 | 1 | 81 | 11 | 48 | 18 | 114 | 43 | ST355 | This study |
| BAL 266 | 3,774,702 (38.86) | 43.8x | 3,645 | 1 | 15 | 13 | 12 | 4 | 163 | 2 | ST585 | This study |
| ATCC19606 | 3,974,237 (39.06) | 49.6x | 3,894 | 1 | 10 | 8 | 6 | 1 | 110 | 14 | New | [34, 35] |
Bp = approximate genome size in base pairs, CDSs = Prokka predicted number of coding sequences, ST = Multilocus sequence typing (MLST) sequence type. gltA, gyrB, gdhB, recA, cpn60, gpi and rpoD are MLST scheme genes, unique alleles given unique number and combination of seven alleles define a strain ST.
A. baumannii susceptibilities to Colistin in vitro.
| Isolate | Minimum inhibitory concentration against colistin μg/ul | ||||
|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | |
| BAL 062 | 0.5 | 0.75 | >256 | >256 | >256 |
| BAL 242 | 0.5 | 32 | 48 | 192 | 192 |
| BAL 255 | 0.5 | 0.75 | 48 | 128 | >256 |
| BAL 266 | 1.5 | 6 | 64 | 96 | 128 |
| ATCC19606 | 0.5 | 16 | >256 | >256 | >256 |
Summary of mutations in colistin resistant progeny.
| Strain | MIC to Colistin (ug/ml) | LpxA (262) | LpxC (300) | LpxD (356) | PmrB (444) | PheS (326) | ZndP (992) | PldA (383) | VacJ (299) | 135 (255) | Ttg2C (226) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BAL062 | 0.5 | ||||||||||
| BAL062-Day2 | 0.75 | ||||||||||
| BAL062-Day5 | >256 | T319R (325) | N104M (105) | ||||||||
| BAL242 | 0.5 | ||||||||||
| BAL242-Day2 | 32 | T319R (325) | |||||||||
| BAL242-Day3 | 48 | STOP (229) | |||||||||
| BAL242-Day5 | 192 | STOP (229) | Q249T (257) | ||||||||
| BAL255 | 0.5 | ||||||||||
| BAL255-Day2 | 0.75 | ||||||||||
| BAL255-Day3 | 48 | A141T | H242L | ||||||||
| BAL255-Day4 | 128 | H242L | F149L (165) | ||||||||
| BAL255-Day5 | >256 | H242L | W179C (186) | ||||||||
| BAL266 | 1.5 | ||||||||||
| BAL266-Day2 | 6 | ||||||||||
| BAL266-Day3 | 16 | P30L | T200T (209) | ||||||||
| BAL266-Day4 | 96 | R134C, G315S | |||||||||
| BAL266-Day5 | 128 | Y194S, G315S | N138S | ||||||||
| ATCC19606 | 0.5 | ||||||||||
| ATCC19606-Day3 | >256 | R166N (135) | |||||||||
| ATCC19606-Day5 | >256 | Y111C (127) |
135 = A. baumannii AB307-0294 CDS ABBFA_000135 homologue annotated as ‘hypothetical protein.
*indicates a synonymous change gca- >gcg (A->A) was also present.
†Denotes a frameshift due to a nucleotide deletion/insertion resulting in a truncated protein, (xx) indicates the size of full/truncated protein in amino acids, STOP indicates a C to T SNP that generates a TAA stop codon.